date,username,to,replies,retweets,favorites,text,geo,mentions,hashtags,id,permalink
2020-03-08 18:42:52,DrugsJournal,,0,0,0,"Issue #4 of @DrugsJournal now available including first approval reports on lumateperone (CAPLYTA) in #schizophrenia, lemborexant (DAYVIGO) in #insomnia, avapritinib (AYVAKIET) in GIST and sodium oligomannate in China for #Alzheimers",,@DrugsJournal,#schizophrenia #insomnia #Alzheimers,1236724079048019968,https://twitter.com/DrugsJournal/status/1236724079048019968
2020-03-04 01:44:34,hitman0307,,0,0,0,"Caplyta 42 mg capsules (lumateperone) will be just over $40 per capsule, making it the most expensive oral antipsychotic on the market, about $2-3/unit more costly than Vraylar (cariprazine) and Latuda (lurasidone). $ITCI",,,,1235018262817185793,https://twitter.com/hitman0307/status/1235018262817185793
2020-03-03 11:36:04,semodough,,0,1,1,"Laden $ITCI: CAPLYTA Launch in March 2020; Pivotal BP Study Initiated; Buy &amp; Lower PT to $40",,,,1234804733631770624,https://twitter.com/semodough/status/1234804733631770624
2020-03-03 00:45:02,SiteFocusHQ,,0,0,0,"$ITCI Earnings Intelligence Analysis of recent earnings identified Intra-Cellular Therapies Inc (NASDAQ: ITCI ) business focus on (bipolar,bipolar_ii,lumateperone,milligrams), (adjunctive,bipolar,bipolar_ii,lumateperone), (caplyta,medical) https://www.sitefocus.com/cif/ei/cd_itci509420200302",,,,1234640894239727617,https://twitter.com/SiteFocusHQ/status/1234640894239727617
2020-02-21 18:19:40,psychopharmacol,,1,1,0,"FDA approved Caplyta (lumateperone) to treat schizophrenia in adults. Therapeutic advantages over current medications have not been reported, A ""me-too"" medication? Lumateperone has increased binding at the 5-HT2A r. without excess binding to the D2 r. ",,,,1230920034429612032,https://twitter.com/psychopharmacol/status/1230920034429612032
2020-02-21 00:04:02,Briefingcom,,0,0,0,"$ITCI: Intra-Cellular Therapies announces publication of CAPLYTA results in JAMA Psychiatry http://bit.ly/2vSK8ZG",,,,1230644308404928512,https://twitter.com/Briefingcom/status/1230644308404928512
2020-02-20 22:38:35,TINMobileNews,,0,0,0,"Intra-Cellular says CAPLYTA study results published in JAMA Psychiatry (The Fly) http://dlvr.it/RQRX0V",,,,1230622805189787648,https://twitter.com/TINMobileNews/status/1230622805189787648
2020-02-07 22:12:39,dtwResearchInc,,0,0,0,"In Q4, Intra-Cellular Therapies Debutes New Website For Caplyta #intracellulartherapies #CAPLYTA #availablemarch2020 #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS #newwebsite #q4 #q42019 #dtwmarkethighlight",,,#intracellulartherapies #CAPLYTA #availablemarch2020 #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS #newwebsite #q4 #q42019 #dtwmarkethighlight,1225905235442491392,https://twitter.com/dtwResearchInc/status/1225905235442491392
2020-01-29 18:22:32,Anton_Pearce,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia http://dlvr.it/RP0FXY",,,,1222585836698341377,https://twitter.com/Anton_Pearce/status/1222585836698341377
2020-01-29 03:49:22,HealthcareBeat,,0,0,0,"Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA $ITCI",,,,1222366095539044352,https://twitter.com/HealthcareBeat/status/1222366095539044352
2020-01-24 17:18:51,DrDarrenRFlower,,0,2,4,"FDA approves lumateperone (brand name: Caplyta) as an oral, once-a-day treatment for adult #schizophrenia. #drugs #drugdiscovery https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,#schizophrenia #drugs #drugdiscovery,1220757872126169088,https://twitter.com/DrDarrenRFlower/status/1220757872126169088
2020-01-23 22:18:50,Nurani05716217,,0,0,0,"@jimcramer hi Jim, recently bought stock in Intercellular therapies ITCI, when the announcement of the approval of the Caplyta. But now I am losing money. Should I sell or hold? #cramer",,@jimcramer,#cramer,1220470974409248768,https://twitter.com/Nurani05716217/status/1220470974409248768
2020-01-21 15:15:40,TranspariMED,,1,4,8,"Very interesting and detailed criticism of the design of a clinical trial used as basis for FDA approval for the drug #lumateperone (#Caplyta) Comment: Trial designs should be open to public review BEFORE a trial starts, not when it is too late ",,,#lumateperone #Caplyta,1219639708176781313,https://twitter.com/TranspariMED/status/1219639708176781313
2020-01-21 03:39:06,NickWebb30,,1,0,0,"""In trials, Caplyta did not cause akathisia, a feeling of jitteriness among patients, which is extraordinarily uncomfortable and makes people “jump out of their skin”, the company said."" ",,,,1219464410596438017,https://twitter.com/NickWebb30/status/1219464410596438017
2020-01-20 04:01:15,awaisaftab,Mad_In_America,0,8,15,"An extremely sad state of affairs... the meticulous attention to detail, robust scrutiny, and transparent reporting that should be the hallmark of research published in top psychiatry journals is completely absent in Caplyta trials &amp; other instances of pharma sponsored research ",,,,1219107595002294272,https://twitter.com/awaisaftab/status/1219107595002294272
2020-01-18 03:06:02,DrugStoreNews,,0,0,0,"Intra-Cellular plans to launch Caplyta, which is indicated for the treatment of schizophrenia in adults, in the first quarter of this year. https://buff.ly/2uDWBQm",,,,1218368924594642944,https://twitter.com/DrugStoreNews/status/1218368924594642944
2020-01-15 10:25:18,Dra_TeraizaMesa,,0,0,0,"Psych News Alert: FDA Approves Caplyta to Treat Schizophrenia in Adults http://alert.psychnews.org/2019/12/fda-approves-caplyta-to-treat.html?m=1",,,,1217392304098566145,https://twitter.com/Dra_TeraizaMesa/status/1217392304098566145
2020-01-14 18:40:02,DynaMed_EBSCO,,0,0,1,"Lumateperone (Caplyta) @US_FDA approved for #schizophrenia in adults. Find the evidence in DynaMed: https://ebsco.is/DM011320-3 #Psychiatry #MentalHealth",,@US_FDA,#schizophrenia #Psychiatry #MentalHealth,1217154423169961986,https://twitter.com/DynaMed_EBSCO/status/1217154423169961986
2020-01-13 15:15:45,PatientWorthy,,0,1,2,"Schizophrenia Patients in the United States Now Have a New Treatment Option http://bit.ly/3a6dWlh #schizophrenia #caplyta @sardaa_org",,@sardaa_org,#schizophrenia #caplyta,1216740625216950274,https://twitter.com/PatientWorthy/status/1216740625216950274
2020-01-11 13:44:09,Getrealorelse,NextGenStock,0,0,0,"one special feature of caplyta is its good safety profile, drowsiness and dry mouth, while current meds, even the 2nd gen ones, are plagued with worrisome side effects such as increase blood sugar and lipid, weight gain, parkinsonism, tardive dyskinesia, etc.",,,,1215992798836641793,https://twitter.com/Getrealorelse/status/1215992798836641793
2020-01-11 08:50:43,contrariansmind,,0,0,0,"Intra-Cellular Therapies (ITCI) Receives FDA Approval of Novel Antipsychotic, CAPLYTA for Treatment of Schizophrenia in Adults http://www.streetinsider.com/Corporate+News/Intra-Cellular+Therapies+%28ITCI%29+Receives+FDA+Approval+of+Novel+Antipsychotic%2C+CAPLYTA+for+Treatment+of+Schizophrenia+in+Adults/16271036.html via @Street_Insider",,@Street_Insider,,1215918951185645568,https://twitter.com/contrariansmind/status/1215918951185645568
2020-01-11 07:32:02,PharmDigest,,0,0,0,"Drug Trials Snapshots: CAPLYTA ",,,,1215899149087887360,https://twitter.com/PharmDigest/status/1215899149087887360
2020-01-11 00:25:02,DeliveryDrug,,0,0,0,"Drug Trials Snapshots CAPLYTA: CAPLYTA is a drug used for the treatment of schizophrenia in adults. ",,,,1215791691703021568,https://twitter.com/DeliveryDrug/status/1215791691703021568
2020-01-11 00:25:02,PharmacyBio,,0,1,0,"Drug Trials Snapshots CAPLYTA: CAPLYTA is a drug used for the treatment of schizophrenia in adults. http://bioportfol.io/RMqJP7 #pharmacy",,,#pharmacy,1215791691149369344,https://twitter.com/PharmacyBio/status/1215791691149369344
2020-01-10 17:07:30,content_catcher,,0,0,0,"New Data on First-In-Class Antipsychotic: The novel antipsychotic lumateperone (Caplyta… ",,,,1215681584625541120,https://twitter.com/content_catcher/status/1215681584625541120
2020-01-10 15:22:06,semodough,,1,2,14,"RBC $ITCI BUY PT 38 KOL Call Underscores Caplyta Potential For Differentiation and Adoption In Schizophrenia-highlighting likelihood its more benign tolerability profile will drive meaningful adoption,expressing enthusiasm around its unique mechanism",,,,1215655057334718470,https://twitter.com/semodough/status/1215655057334718470
2020-01-09 17:04:01,medpagetoday,,0,0,0,"This #schizophrenia drug improved psychotic symptoms in trial, but that's not the whole story. By @hlavinka_e. #Caplyta @JAMAPsych",,@hlavinka_e @JAMAPsych,#schizophrenia #Caplyta,1215318317633802240,https://twitter.com/medpagetoday/status/1215318317633802240
2020-01-09 15:35:57,NextGenStock,,2,0,3,"$ITCI picked up a starter under $26. #FDA approved their drug #CAPLYTA for treatment of schizophrenia. Market is bigger than $ACAD #drug for #Parkinsons #psychosis @7.2B MC. They also have a #drug in a 3rd trial in #bipolar disease. It should at least be 3-5B MS right now IMHO.",,,#FDA #CAPLYTA #drug #Parkinsons #psychosis #drug #bipolar,1215296157985005568,https://twitter.com/NextGenStock/status/1215296157985005568
2020-01-09 14:57:49,dshoemakerpaps,,0,0,0,"Some Caplyta Results in Schizophrenia Reach Print https://www.medpagetoday.com/psychiatry/schizophrenia/84265",,,,1215286558150025228,https://twitter.com/dshoemakerpaps/status/1215286558150025228
2020-01-08 22:01:51,dtwResearchInc,,0,0,0,"CAPLYTA is now FDA approved for the treatment of schizophrenia For more information: https://dtw.bz/CAPLYTA #intracellulartherapies #CAPLYTA #newdrug #FDAapproved #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS",,,#intracellulartherapies #CAPLYTA #newdrug #FDAapproved #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS,1215030885302571011,https://twitter.com/dtwResearchInc/status/1215030885302571011
2020-01-08 14:21:15,giulietti_Rx,,0,0,0,"Interesting new anti-psych Caplyta with claimed better safety profile than current standards, I think still will have to see how it performs on a large scale to really test its safety profile #twitterx",,,#twitterx,1214914968275030016,https://twitter.com/giulietti_Rx/status/1214914968275030016
2020-01-08 14:16:31,sweenprs,M9196,0,0,0,"Like caplyta, which is a first in class drug to treat schizophrenia? Or Enhertu, which is for breast cancer? Or the Ebola vaccine Ervebo? How about Nouress, which is for critical neonatal care? Yeah, I'm sure those wont help anyone. At least you're clear on ""you"" first.",,,,1214913777931554816,https://twitter.com/sweenprs/status/1214913777931554816
2020-01-07 20:35:28,BrandonPKoch,,0,0,0,"$ITCI biotech name with momentum behind it, ""The main development behind the jump is the FDA approval of Caplyta, a drug for the treatment of schizophrenia in adults."" - The company expects the drug to be available in pharmacies by the end of March 2020. ",,,,1214646755351912448,https://twitter.com/BrandonPKoch/status/1214646755351912448
2020-01-07 02:42:31,RockRat2,JamesEKrause,0,0,0,"I haven't followed ITCI very closely this past year. The slight pullback coming with the secondary has me wondering: have they articulated a marketing strategy for Caplyta? No presentations on the website right now JPM in about a week, though).",,,,1214376738714578944,https://twitter.com/RockRat2/status/1214376738714578944
2020-01-06 09:14:19,reesprescribe,,0,1,0,"First in Class Schizophrenia drug Lumateperone (Caplyta) approved by FDA. A Serotonin-Dopamine Activity Modulator (SDAM) once daily oral agent ://www.medscape.com/viewarticle/923046?src=soc_tw_share via @medscape",,@Medscape,,1214112951000555520,https://twitter.com/reesprescribe/status/1214112951000555520
2020-01-05 13:11:34,Dra_TeraizaMesa,,0,0,0,"Psych News Alert: FDA Approves Caplyta to Treat Schizophrenia in Adults http://alert.psychnews.org/2019/12/fda-approves-caplyta-to-treat.html?m=1",,,,1213810268184162304,https://twitter.com/Dra_TeraizaMesa/status/1213810268184162304
2020-01-03 22:45:07,Carepatron1,,0,0,0,"This week the U.S. Food and Drug Administration (FDA) approved a new drug — Caplyta (lumateperone), which will give people living with schizophrenia a new approach to treatment. It is expected to be available in early 2020. ",,,,1213229830814208002,https://twitter.com/Carepatron1/status/1213229830814208002
2020-01-03 17:20:04,NAMIMinnesota,,0,1,3,"The US Food and Drug Administration (FDA) has approved lumateperone (Caplyta), a novel antipsychotic from Intra-Cellular Therapies, Inc., for the treatment of schizophrenia in adults. ",,,,1213148033061396482,https://twitter.com/NAMIMinnesota/status/1213148033061396482
2020-01-03 15:07:16,halfvietguy,,0,0,0,"FYI. FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1213114609000804353,https://twitter.com/halfvietguy/status/1213114609000804353
2020-01-02 15:37:18,rgalehouse1,,2,0,1,"$ITCI IMO Caplyta best in class. Treats both positive and negative (hard to treat) symptoms. An advantage over current drugs. Treats depression also, which is symptom of schizophrenia. EPS same as placebo. Weight gain, fasting blood sugar, triglycerides, and cholesterol, same",,,,1212759779946487808,https://twitter.com/rgalehouse1/status/1212759779946487808
2020-01-02 02:48:04,NewExpressNews,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults https://www.winway.me/health-remedies/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/ via @WinWay Health Blog",,@WINWAY,,1212566195402149888,https://twitter.com/NewExpressNews/status/1212566195402149888
2020-01-02 01:37:20,Drugscom,,0,1,1,"Even at year’s end, novel drugs gain FDA-clearance. Caplyta is a first-in-class antipsychotic for schizophrenia and Dayvigo is the latest insomnia option. Plus, a recap of 2019 drug approvals. Happy New Year from the team at http://Drugs.com! https://www.drugs.com/newsletters/weekly/weekly-news-round-up-january-1-2020-1448.html",,,,1212548395761451008,https://twitter.com/Drugscom/status/1212548395761451008
2020-01-01 23:55:10,ForTheRecord01,,0,0,4,"Antipsychotic Drugs: Why Nuplazid is Best in Class - It doesn't cause weight gain. - It doesn't sedate patients (unlike Caplyta). - It doesn't cause tardive dyskinesia (unlike Seroquel et al.). - It doesn't worsen motor symptoms. - It doesn't exacerbate cognitive decline. $ACAD",,,,1212522686255026176,https://twitter.com/ForTheRecord01/status/1212522686255026176
2020-01-01 21:13:24,MedPipeline,,0,0,0,"Even at year’s end, novel drugs gain #FDA-clearance. Caplyta is a first-in-class antipsychotic for schizophrenia and Dayvigo is the latest insomnia option. Plus, see a recap of 2019 drug approvals. Happy New Year from the team at http://Drugs.com! https://www.drugs.com/newsletters/weekly/weekly-news-round-up-january-1-2020-1448.html",,,#FDA,1212481975992356865,https://twitter.com/MedPipeline/status/1212481975992356865
2020-01-01 17:44:39,escalatescience,,0,0,0,"Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turns https://www.escalatesciences.com/post/intra-cellular-nabs-nod-for-schizophrenia-drug-caplyta-after-fda-twists-and-turns",,,,1212429443681181697,https://twitter.com/escalatescience/status/1212429443681181697
2019-12-31 19:55:23,schizofriendian,,0,0,0,"Approval of Caplyta ",,,,1212099952899502086,https://twitter.com/schizofriendian/status/1212099952899502086
2019-12-31 03:28:46,benpowers3,,0,0,1,"$ITCI ""We believe Caplyta provides health care providers a new, safe and effective treatment option to help millions of adult patients with schizophrenia,"" ",,,,1211851664887558144,https://twitter.com/benpowers3/status/1211851664887558144
2019-12-29 16:11:03,drfranktarazi,,0,3,5,"In 2019, #FDA approved 11 new drugs for #brain disorders. #Zulresso (#PPD), #Wakix &amp; #Sunsoi (#narcolepsy), #Reyvow &amp; #Ubrelvy (#migraines), #Mayzent (#MS), #Xcopri (#epilepsy), #Caplyta (#schizophrenia), #Dayvigo (#insomina), #Nourianz (#Parkinsons), &amp; #Vyondys53 for #DMD!",,,#FDA #brain #Zulresso #PPD #Wakix #Sunsoi #narcolepsy #Reyvow #Ubrelvy #migraines #Mayzent #MS #Xcopri #epilepsy #Caplyta #schizophrenia #Dayvigo #insomina #Nourianz #Parkinsons #Vyondys53 #DMD,1211318724562706432,https://twitter.com/drfranktarazi/status/1211318724562706432
2019-12-28 22:55:40,jolivei1967,,0,0,0,"Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turns ",,,,1211058161802731526,https://twitter.com/jolivei1967/status/1211058161802731526
2019-12-28 14:21:06,DrWinarick,,0,2,3,"FDA Approves Caplyta to Treat Schizophrenia in Adults ",,,,1210928664721928192,https://twitter.com/DrWinarick/status/1210928664721928192
2019-12-28 11:15:31,HeraklesTrading,,0,0,1,"$ITCI Again: if you read the comments sent to the AdCom you would understand that CAPLYTA is likely to become standard of care quickly without too much on marketing costs!! now after fda approval this a 3-4bn market cap ... ",,,,1210881963856453639,https://twitter.com/HeraklesTrading/status/1210881963856453639
2019-12-28 09:03:57,ApoThera,,0,0,0,"Lumateperone tosylate (Caplyta) has been approved for treating schizophrenia. Drug Information for Lumateperone tosylate (Caplyta) is available on @ApoThera https://apps.apple.com/us/app/apothera/id526613282 #Psychiatry #mentalhealth #mHealth #hcsm #hcsmeu #medschool #medstudenttwitter #medtwitter",,@ApoThera,#Psychiatry #mentalhealth #mHealth #hcsm #hcsmeu #medschool #medstudenttwitter #medtwitter,1210848852393123840,https://twitter.com/ApoThera/status/1210848852393123840
2019-12-27 22:36:57,Afrazzaman,,0,0,0,"FDA approves Caplyta to treat schizophrenia in adults https://www.mdedge.com/psychiatry/article/214733/schizophrenia-other-psychotic-disorders/fda-approves-caplyta-treat",,,,1210691062420783105,https://twitter.com/Afrazzaman/status/1210691062420783105
2019-12-27 16:02:28,SurgingEarnings,,0,1,0,"Intra-Cellular Therapies $ITCI soared after FDA approval for Caplyta for treating schizophrenia. The stock is now up 200% with a market capitalization of $2 billion but still looks reasonable compared to a TAM of $15 billion #stocks",,,#stocks,1210591788014157824,https://twitter.com/SurgingEarnings/status/1210591788014157824
2019-12-27 15:11:35,NowPsych,,0,0,0,"RT PsychiatricNews: The US_FDA this week approved Caplyta (lumateperone), an oral atypical antipsychotic medication to treat #schizophrenia in adults. http://apapsy.ch/blg-fda-caplyta #MentalHealth",,,#schizophrenia #MentalHealth,1210578982363639808,https://twitter.com/NowPsych/status/1210578982363639808
2019-12-27 15:08:49,PsychiatricNews,,0,4,2,"The @US_FDA this week approved Caplyta (lumateperone), an oral atypical antipsychotic medication to treat #schizophrenia in adults. http://apapsy.ch/blg-fda-caplyta #MentalHealth",,@US_FDA,#schizophrenia #MentalHealth,1210578286801281024,https://twitter.com/PsychiatricNews/status/1210578286801281024
2019-12-27 09:15:02,kkmaggon,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults http://sco.lt/5UtAvY",,,,1210489251437121536,https://twitter.com/kkmaggon/status/1210489251437121536
2019-12-27 08:45:29,GMPnewsNet,,0,0,0,"Caplyta Gained FDA Clearance for Schizophrenia Treatment - https://is.gd/h9PgjM",,,,1210481817343725568,https://twitter.com/GMPnewsNet/status/1210481817343725568
2019-12-27 06:38:17,DrTranBioSci,,1,0,0,"Here's my holiday weekend gift to you. This is how I forecasted Caplyta's approval. https://seekingalpha.com/instablog/17806842-biosci-capital-partners/5390169-intra-cellular-therapies-forecasting-upcoming-approval #DrTranBioSci #Investments #Biotech #StocksToWatch #IntraCellularTherapies $ITCI",,,#DrTranBioSci #Investments #Biotech #StocksToWatch #IntraCellularTherapies,1210449807841615873,https://twitter.com/DrTranBioSci/status/1210449807841615873
2019-12-27 06:31:17,HansBangen,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1210448043234996224,https://twitter.com/HansBangen/status/1210448043234996224
2019-12-26 18:34:03,aghoury79,,0,0,0,"FDA Approves Caplyta to Treat Schizophrenia in Adults ",,,,1210267546529751043,https://twitter.com/aghoury79/status/1210267546529751043
2019-12-25 21:14:06,luismariani,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209945436892651521,https://twitter.com/luismariani/status/1209945436892651521
2019-12-25 08:43:25,alessiobiagimd,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia ",,,,1209756519983648768,https://twitter.com/alessiobiagimd/status/1209756519983648768
2019-12-24 23:18:28,britishroses1,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209614347917500418,https://twitter.com/britishroses1/status/1209614347917500418
2019-12-24 22:52:10,dwitb,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia https://www.medscape.com/viewarticle/923046?src=soc_tw_share via @medscape",,@Medscape,,1209607728907378689,https://twitter.com/dwitb/status/1209607728907378689
2019-12-24 22:07:11,AdveraHealth,,0,0,0,"Intra-Cellular nabs nod for #schizophrenia drug Caplyta after FDA twists and turns | FiercePharma https://hubs.ly/H0mn8Hv0",,,#schizophrenia,1209596408397025285,https://twitter.com/AdveraHealth/status/1209596408397025285
2019-12-24 19:21:36,shamaimri,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209554736627757056,https://twitter.com/shamaimri/status/1209554736627757056
2019-12-24 18:29:24,DrugscomNew,,0,3,2,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults - ",,,,1209541600097062912,https://twitter.com/DrugscomNew/status/1209541600097062912
2019-12-24 18:29:24,Drugscom,,0,3,1,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults - ",,,,1209541599023243264,https://twitter.com/Drugscom/status/1209541599023243264
2019-12-24 15:24:23,ByJoFagg,,0,2,0,"I had a look at Ubrelvy's approval, Biohaven isn't far behind $AGN $BHVN #ubrogepant while @LizVantage delved into the surprising green light for Caplyta #lumateperone $ITCI https://www.evaluate.com/vantage/articles/news/snippets/ubrelvys-winner-not-long https://www.evaluate.com/vantage/articles/news/snippets/intra-cellular-triples-schizophrenia-approval",,@LizVantage,#ubrogepant #lumateperone,1209495040407605249,https://twitter.com/ByJoFagg/status/1209495040407605249
2019-12-24 15:22:50,Cemhri,,0,0,0,"The US Food and Drug Administration (FDA) has approved lumateperone (Caplyta, Intra-Cellular Therapies, Inc) for treatment of schizophrenia in adults. https://www.medscape.com/viewarticle/923046?src=soc_tw_191226_mscpedt_news_mdscp_schizophrenia&amp;faf=1",,,,1209494650177888256,https://twitter.com/Cemhri/status/1209494650177888256
2019-12-24 15:19:32,DalyMcEverK,,0,0,1,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia Has it been determined if #Schizophrenia is acquired, biological, or #genetic, or combo of genetic predisposition augmented by biology or environment? Meds don’t help exogenous causes https://www.medscape.com/viewarticle/923046",,,#Schizophrenia #genetic,1209493820959838209,https://twitter.com/DalyMcEverK/status/1209493820959838209
2019-12-24 15:00:30,PharmacyWeek,,0,0,0,"FDA Approves Lumateperone For Schizophrenia With Boxed Warning Reuters reports the FDA approved Intra-Cellular Therapies Inc.’s Caplyta (lumateperone) “as a once-daily dose of 42 mg” for the treatment of schizophrenia. The company said it plans ... https://buff.ly/2ELHuX5",,,,1209489027944071168,https://twitter.com/PharmacyWeek/status/1209489027944071168
2019-12-24 13:59:47,zipjet,,0,0,0,"Biotech Values: ($ITCI)&mdash; $BMY has a financial stake in Caplyta, based ",,,,1209473749772316673,https://twitter.com/zipjet/status/1209473749772316673
2019-12-24 11:20:01,MedPipeline,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209433541416800256,https://twitter.com/MedPipeline/status/1209433541416800256
2019-12-24 01:06:03,Dr_Roufy,,0,0,1,"Lumateperone (Caplyta): New Antipsychotic Approved for Schizophrenia ",,,,1209279034162601989,https://twitter.com/Dr_Roufy/status/1209279034162601989
2019-12-23 23:00:17,NewExpressNews,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209247383432900609,https://twitter.com/NewExpressNews/status/1209247383432900609
2019-12-23 22:51:21,fdadaily,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults, ,https://fdadaily.com/2019/12/23/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/",,,,1209245134098972672,https://twitter.com/fdadaily/status/1209245134098972672
2019-12-23 22:39:05,FeedHcp,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults,,https://www.hcpfeed.com/2019/12/23/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/,",,,,1209242047900798976,https://twitter.com/FeedHcp/status/1209242047900798976
2019-12-23 22:16:43,drhatton,,0,0,1,"#FDAapproves #Caplyta (#lumateperone) for schizophrenia. Do you know how to say the generic name? Lew-mah-TEH-pur-own #pronunciation #PROnounce #ProDataHealth",,,#FDAapproves #Caplyta #lumateperone #pronunciation #PROnounce #ProDataHealth,1209236420914663424,https://twitter.com/drhatton/status/1209236420914663424
2019-12-23 21:11:51,jaimy_lee,,0,1,2,"Today's FDA approval of Intra-Cellular Therapeutics's schizophrenia drug Caplyta gives us hints to how the regulator will think about Biogen's controversial Alzheimer's candidate (and other 'neuroscience' drugs), one analyst said. $ITCI $BIIB $JN $SAGE",,,,1209220094607446018,https://twitter.com/jaimy_lee/status/1209220094607446018
2019-12-23 20:55:31,semodough,,1,7,14,"BTIG Intra-Cellular Therapies, Inc. $ITCI, Buy, $73 PT): Caplyta (Lumateperone) Approved in Schizophrenia – Relatively Clean Label Bodes Well for Solid Uptake for Its 1Q20 Launch – Target to $73",,,,1209215986131439620,https://twitter.com/semodough/status/1209215986131439620
2019-12-23 20:10:48,FouadMaanane,,0,0,0,"Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turns ",,,,1209204732490866691,https://twitter.com/FouadMaanane/status/1209204732490866691
2019-12-23 20:06:32,art2i,Investingcom,0,0,0,"Intra-Cellular Therapies $ITCI, a biopharma on CNS disorders, eg. Parkinson's, dementia, schizophrenia, bipolar disorder, autism, etc. $ITCI jumped 200% on FDA approval today of its CAPLYTA®/#Lumateperone for schizophrenia treatment in adults",,,#Lumateperone,1209203655636746240,https://twitter.com/art2i/status/1209203655636746240
2019-12-23 20:00:07,EpicsFinance,,0,0,0,"Investors flock to neuro drug makers after FDA approves new schizophrenia drug The approval of Intra-Cellular Therapies Inc.’s schizophrenia drug Caplyta on Monday is the latest indicator that some drug developers are finally prioritizing psychiatric t http://www.marketwatch.com/news/story.asp?guid=%7BCFF45B10-25A5-11EA-8685-7B4683E27101%7D&amp;siteid=rss&amp;rss=1",,,,1209202043849756673,https://twitter.com/EpicsFinance/status/1209202043849756673
2019-12-23 18:55:41,KKurbs,,0,0,0,"Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turns http://twib.in/l/5j7444djezey #pharma",,,#pharma,1209185829224099841,https://twitter.com/KKurbs/status/1209185829224099841
2019-12-23 18:48:22,Health4Soul,,0,0,1,"Intracellular Therapies Inc ($ITCI) who focuses on Central nervous system psychiatric and neurodegenerative disorders was approved by the FDA to release CAPLYTA® (lumateperone) to the market. This news catalyzed a 200%+ gain intra…https://lnkd.in/dpHUt6k",,,,1209183985538084873,https://twitter.com/Health4Soul/status/1209183985538084873
2019-12-23 18:43:38,pharmacopsych,,0,0,1,"Lumateperone (IntraCellular Therapies; Caplyta) has been approved for the treatment of schiphrenia in adults. PANSS Total Score at 4 weeks NNT=20. Common drug related adverse effects are somnolence/sedation (NNH=7.14) and dry mouth (NNH=25). https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,,1209182793353162755,https://twitter.com/pharmacopsych/status/1209182793353162755
2019-12-23 18:31:51,semodough,,2,0,5,"mouth. We believe this strong label will position CAPLYTA as a new option for treating patients with schizophrenia",,,,1209179831444942850,https://twitter.com/semodough/status/1209179831444942850
2019-12-23 18:31:51,semodough,,1,0,5,"CAPLYTA label is favorable as it received only warnings&amp;precautions found in other atypical antipsychotics. Specifically, label mentioned improvements in safety, extrapyramidal symptoms (EPS)&amp;metabolic profile (weight gain) with most common adverse events being somnolence dry",,,,1209179828760580101,https://twitter.com/semodough/status/1209179828760580101
2019-12-23 18:30:36,semodough,,2,0,7,"Laden $ITCI: Lumateperone (CAPLYTA) Approved; Commercial Launch 1Q20; Buy and PT $58.",,,,1209179516519768064,https://twitter.com/semodough/status/1209179516519768064
2019-12-23 18:25:00,BioPharmaDive,,1,1,2,"Lumateperone, to be sold as Caplyta, had conflicting results in late-stage trials​. Its approval suggests the FDA is using a ""glass half full lens"" to review neuroscience drugs, said one analyst ",,,,1209178104683327490,https://twitter.com/BioPharmaDive/status/1209178104683327490
2019-12-23 17:53:04,BrainSightsApp,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia - Medscape - Neurology via BrainSights for iOS ",,,,1209170067755323392,https://twitter.com/BrainSightsApp/status/1209170067755323392
2019-12-23 16:48:40,HealioPsych,,0,0,0,"The FDA has approved Caplyta for the treatment of schizophrenia in adults, according to a press release from the agent’s manufacturer. ",,,,1209153863229616128,https://twitter.com/HealioPsych/status/1209153863229616128
2019-12-23 16:30:40,NASDAQODUK,,0,0,0,"$ITCI Intra-Cellular Therapies announces CAPLYTA (lumateperone) has been approved by the FDA for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020. Stock skyrocketed.",,,,1209149332697600002,https://twitter.com/NASDAQODUK/status/1209149332697600002
2019-12-23 16:25:25,_B_I_O_T_E_C_H_,lblegend33,1,0,0,"cantor: Ringing In Cheer - Green Flag Flies with CAPLYTA Approval - Raising PT We reiterate our Overweight rating and increase our price target to $43 from $27 on $ITCI shares.",,,,1209148012976582659,https://twitter.com/_B_I_O_T_E_C_H_/status/1209148012976582659
2019-12-23 15:40:49,ivolatility,,0,0,0,"$ITCI: DAILY 1 YEAR VOLATILITY CHART into announces FDA approval of CAPLYTA ",,,,1209136787278483457,https://twitter.com/ivolatility/status/1209136787278483457
2019-12-23 15:40:05,MarketWN,,0,0,1,"$ITCI News Article - FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults https://marketwirenews.com/news-releases/fda-approves-intra-cellular-therapies-novel-antipsyc-8786777563079734.html #GetYourMoneyRight @Doubleozoe @iamcryptomonkey @DekmarTrades $UURAF $ITCI $TAUG",,@Doubleozoe @iamcryptomonkey @DekmarTrades,#GetYourMoneyRight,1209136604331356160,https://twitter.com/MarketWN/status/1209136604331356160
2019-12-23 15:37:37,FiercePharma,,0,3,3,"Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turns https://www.fiercepharma.com/pharma/intra-cellular-after-fda-review-twists-and-turns-nabs-nod-for-schizophrenia-drug-caplyta",,,,1209135980822908928,https://twitter.com/FiercePharma/status/1209135980822908928
2019-12-23 15:34:54,BiotechAnalysst,,0,0,0,"$ITCI RBC Intra-Cellular Therapies, Inc. - ""Lyt"" At The End Of The Tunnel, As Caplyta Approval Transforms Story; Raise Tgt To $38",,,,1209135297495220225,https://twitter.com/BiotechAnalysst/status/1209135297495220225
2019-12-23 15:25:24,ByJoFagg,,0,0,0,"Caplyta/lumateperone FDA approved, $ITCI shares up 169%",,,,1209132907475984385,https://twitter.com/ByJoFagg/status/1209132907475984385
2019-12-23 15:02:47,TraderSara,,0,1,2,"$ITCI FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults https://pro.benzinga.com/?afmc=5s #daytrade #daytrading #stocks #stockmarketnews #stockstowatch #referrallink",,,#daytrade #daytrading #stocks #stockmarketnews #stockstowatch #referrallink,1209127215218212864,https://twitter.com/TraderSara/status/1209127215218212864
2019-12-23 14:32:01,IBD_AGatlin,,0,0,1,"$ITCI soared roughly 105% in premarket action after the FDA approved its #schizophrenia treatment. The company expects to launch the drug, Caplyta, in late Q1 2020. #biotech #stocks #investingnews",,,#schizophrenia #biotech #stocks #investingnews,1209119473493512192,https://twitter.com/IBD_AGatlin/status/1209119473493512192
2019-12-23 14:30:23,LentilLover,,0,0,0,"FDA approve Caplyta (lumateperone), for treatment of schizophrenia. ",,,,1209119061164142593,https://twitter.com/LentilLover/status/1209119061164142593
2019-12-23 14:29:14,PearlF,,0,0,0,"CAPLYTA (Lumateperone) originally developed by Bristol Myers Squibb and licensed to Intra-Cellular Therapies in 2005. https://www.alzforum.org/therapeutics/lumateperone",,,,1209118774756069376,https://twitter.com/PearlF/status/1209118774756069376
2019-12-23 14:17:31,syinvesting,,0,2,7,"$ITCI (+110% PM) received FDA approval for Caplyta (lumateperone) for the treatment of #schizophrenia in adults. The Company expects to initiate the commercial launch of Caplyta in late Q1 2020. https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,#schizophrenia,1209115825652862976,https://twitter.com/syinvesting/status/1209115825652862976
2019-12-23 14:08:21,psychoBOBlogy,,0,0,0,"""Caplyta, which has been approved as a once-daily dose of 42 mg, has shown to regulate three neurotransmitter systems — serotonin, dopamine and glutamate — linked to severe mental illnesses."" FDA approves Intra-Cellullar's schizophrenia drug https://reut.rs/2MnMPIi",,,,1209113517384765441,https://twitter.com/psychoBOBlogy/status/1209113517384765441
2019-12-23 14:05:17,PearlF,,1,2,11,"FDA approved NYC-based biotech Intra-Cellular Therapies' CAPLYTA for the treatment of schizophrenia in adults. http://bit.ly/2QfbsIa. The company was founded in 2002. CEO is Sharon Mates, PhD. Spinout from Nobel laureate Paul Greengard's lab/Rockefeller. He died in April. $ITCI",,,,1209112744877838337,https://twitter.com/PearlF/status/1209112744877838337
2019-12-23 13:48:14,NewsQuantified,,0,0,0,"FDA Approves $ITCI Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults, stock surges +100.81% ",,,,1209108456503799808,https://twitter.com/NewsQuantified/status/1209108456503799808
2019-12-23 13:35:02,TINMobileNews,,0,0,0,"Intra-Cellular announces FDA approval of CAPLYTA (The Fly) http://dlvr.it/RLpGfq",,,,1209105132786311171,https://twitter.com/TINMobileNews/status/1209105132786311171
2019-12-23 13:27:07,MDMagazine,,0,3,1,"#Breaking: Intra-Cellular Therapies has announced #lumateperone (CAPLYTA) received approval from the FDA for the treatment of #schizophrenia in adults and the company expects the treatment to be available in late Q1 2020.",,,#Breaking #lumateperone #schizophrenia,1209103140135559169,https://twitter.com/MDMagazine/status/1209103140135559169
2019-12-23 13:12:43,GlobalMedEd,,2,10,47,"FDA approves Intra-CellularTherapies #antipsychotic #Caplyta (#lumateperone) for #schizophrenia in adults. Great news for patients!! http://bit.ly/2QbuoHL #nursepractitioner #psychiatry #mh #mhchat #primarycare #familymedicine",,,#antipsychotic #Caplyta #lumateperone #schizophrenia #nursepractitioner #psychiatry #mh #mhchat #primarycare #familymedicine,1209099516743430149,https://twitter.com/GlobalMedEd/status/1209099516743430149
2019-12-23 13:05:10,newsfilterio,,0,1,0,"Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA $ITCI",,,,1209097615691804672,https://twitter.com/newsfilterio/status/1209097615691804672
2019-12-23 13:03:02,StckPro,,0,1,0,"$ITCI NEW ARTICLE : Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA https://dashboard.stck.pro/news.php?ticker=ITCI&amp;rowid=3049848",,,,1209097081899626497,https://twitter.com/StckPro/status/1209097081899626497
2019-12-23 13:01:17,MarketCurrents,,0,1,1,"$ITCI - Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA https://seekingalpha.com/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda?source=feed_f&amp;utm_campaign=twitter_automated&amp;utm_content=news&amp;utm_medium=social&amp;utm_source=twitter",,,,1209096639291383809,https://twitter.com/MarketCurrents/status/1209096639291383809
2019-12-23 12:49:59,psk2329,,0,2,2,"Intra-Cellular Therapies shares are trading higher after the company announced it has received FDA approval for CAPLYTA, the treatment of schizophrenia in adults. $ITCI",,,,1209093794404151297,https://twitter.com/psk2329/status/1209093794404151297
2019-12-23 12:42:38,WCHsueh,,0,1,1,"$ITCI FDA approval of Caplyta for schizophrenia in adults is rocketing the stock premarket.. short interest is at year highs of over 10mm shares, a short squeeze will magnify the uptrend. Time stamp 24 at 7:42am almost doubling from Fri close",,,,1209091946817499136,https://twitter.com/WCHsueh/status/1209091946817499136
2019-12-23 12:37:28,operatingstock,,1,0,2,"My watch-list for today's session is not finalised, but I will be watching $ITCI. Large gap with news catalyst. ""CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults""",,,,1209090646788595716,https://twitter.com/operatingstock/status/1209090646788595716
2019-12-23 12:35:17,otcdynamics,,0,0,0,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Sc https://www.otcdynamics.com/itci-fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/?utm_campaign=twitter&amp;utm_medium=twitter&amp;utm_source=twitter",,,,1209090097032900608,https://twitter.com/otcdynamics/status/1209090097032900608
2019-12-23 12:21:24,drfranktarazi,,0,1,3,"A new #antipsychotic drug has arrived! #FDA approved $ITCI CAPLYTA® (#lumateperone) for treatment of adult #schizophrenia patients! To be launched in Q1 2020! https://www.streetinsider.com/Globe+Newswire/FDA+Approves+Intra-Cellular+Therapies%E2%80%99+Novel+Antipsychotic%2C+CAPLYTA%C2%AE+%28lumateperone%29+for+the+Treatment+of+Schizophrenia+in+Adults/16270988.html",,,#antipsychotic #FDA #lumateperone #schizophrenia,1209086604746403840,https://twitter.com/drfranktarazi/status/1209086604746403840
2019-12-23 12:21:15,hitman0307,,0,0,3,"$ITCI, great news! FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults | Intra-Cellular Therapies Inc. ",,,,1209086566838284288,https://twitter.com/hitman0307/status/1209086566838284288
2019-12-23 12:20:53,fwpharma,,0,1,1,"Intra-Cellular Therapies' Caplyta gains FDA clearance for schizophrenia in adults https://www.firstwordpharma.com/node/1689506 $ITCI",,,,1209086471182966784,https://twitter.com/fwpharma/status/1209086471182966784
2019-12-23 12:12:40,bio_clouseau,,2,3,7,"$ITCI Caplyta label https://www.intracellulartherapies.com/docs/caplyta_pi.pdf Launch late Q1 20",,,,1209084404821311488,https://twitter.com/bio_clouseau/status/1209084404821311488
2019-12-23 12:11:35,biotechhack,,0,4,4,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults $ITCI",,,,1209084130715217921,https://twitter.com/biotechhack/status/1209084130715217921
2019-12-23 12:10:26,Onellymr,,0,0,1,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209083841861881856,https://twitter.com/Onellymr/status/1209083841861881856
2019-12-23 12:08:06,JacksonJennings,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treat... https://finance.yahoo.com/news/fda-approves-intra-cellular-therapies-115910597.html?soc_src=hl-viewer&amp;soc_trk=tw via @YahooFinance",,@YahooFinance,,1209083253778526215,https://twitter.com/JacksonJennings/status/1209083253778526215
2019-12-23 12:07:51,Trade_The_News,,0,0,1,"$ITCI FDA approves novel Antipsychotic, CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults; Expects to initiate commercial launch of CAPLYTA in late 1Q20 (Intra-Cellular Therapies, Inc.) (More at https://www.tradethenews.com/?twtId=11464)",,,,1209083194810814464,https://twitter.com/Trade_The_News/status/1209083194810814464
2019-12-23 12:07:32,BioBreakout,,0,0,2,"$ITCI Intra-Cellular Therapies Receives FDA Approval of Novel Antipsychotic, CAPLYTA for Treatment of Schizophrenia in Adults",,,,1209083112619204608,https://twitter.com/BioBreakout/status/1209083112619204608
2019-12-23 12:03:06,WallStSai,WallStSai,1,1,5,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209081998578462720,https://twitter.com/WallStSai/status/1209081998578462720
2019-12-23 12:03:03,BankTheTrade,,0,0,7,"$ITCI(12.44) up 4 Intra-Cellular announces FDA approval of CAPLYTA - Intra-Cellular Therapies announced that CAPLYTA has been approved by the U.S. FDA for the treatment of schizophrenia in adults.",,,,1209081984385003520,https://twitter.com/BankTheTrade/status/1209081984385003520
2019-12-23 12:02:06,newsfilterio,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® for the Treatment of Schizophrenia in Adults $ITCI https://newsfilter.io/articles/fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-treatment-of--97d272d40b3e1244874484d05d537787",,,,1209081746177675264,https://twitter.com/newsfilterio/status/1209081746177675264
2019-12-23 12:00:41,bear_fuker,,0,0,0,"FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA(R) (lumateperone) for the Treatment of Schizophrenia in Adults $ITCI",,,,1209081387787128833,https://twitter.com/bear_fuker/status/1209081387787128833
2019-12-23 12:00:06,CrweWorld,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizoph http://crweworld.com/article/news-provided-by-globenewswire/1360149/fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults",,,,1209081243435823105,https://twitter.com/CrweWorld/status/1209081243435823105
2019-12-23 11:59:52,BioStocks,,1,16,24,"$ITCI FDA Approves Caplyta for Treatment of Schizophrenia in Adults",,,,1209081183063150592,https://twitter.com/BioStocks/status/1209081183063150592
2019-12-23 11:59:48,IcemanTrading,,0,4,7,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209081165912715265,https://twitter.com/IcemanTrading/status/1209081165912715265
2019-12-23 11:59:34,TheTradeXchange,,0,0,0,"$ITCI: FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209081107318226946,https://twitter.com/TheTradeXchange/status/1209081107318226946
2017-02-24 12:50:33,inventively,,0,0,0,"New trademark 'CAPLYTA' filed by INTRA-CELLULAR THERAPIES, INC. https://inventively.com/search/trademarks/87334055",,,,835109662676635648,https://twitter.com/inventively/status/835109662676635648
